In this video on OncoDaily , during the European Hematology Association (EHA) 2026 Congress, Dr. Sergey Badalyan speaks with Professor Timothy Hughes, Clinical Director in the Precision Cancer Medicine Theme at SAHMRI and Consultant Haematologist at the Royal Adelaide Hospital, on the remarkable journey of CML treatment – from the introduction of imatinib and the rise of second- and third-generation TKIs to the emergence of STAMP inhibitors such as asciminib.
For 25 years, tyrosine kinase inhibitors (TKIs) have transformed the treatment landscape of chronic myeloid leukemia (CML), turning what was once a largely fatal disease into one of the greatest success stories in modern oncology. In this interview, Professor Hughes discusses the latest three-year results from the ASC4FIRST study, highlighting the efficacy, safety, and tolerability advantages of asciminib in the frontline setting. He also explores the remaining challenges in CML care, including improving treatment-free #remission rates, overcoming leukemic cell persistence, enhancing immune control, and continuing to improve patients’ quality of life.